Source comparison
Best Peptides for Stroke Recovery: Research Comparison
BPC-157 Angiogenesis, eNOS stabilization, VEGF upregulation 0–72 hours (acute phase) Subcutaneous 42% infarct volume reduction in rodent MCAO models (2021) Strongest preclinical evidence for acute neuroprotection Cerebrolysin Neurotrophic factor mimicry (BDNF,
This comparison does not assign a generated winner or score.
- BPC-157
- Angiogenesis, eNOS stabilization, VEGF upregulation
- 0–72 hours (acute phase)
- Subcutaneous
- 42% infarct volume reduction in rodent MCAO models (2021)
- Strongest preclinical evidence for acute neuroprotection
- Cerebrolysin
- Neurotrophic factor mimicry (BDNF, NGF, CNTF)
- Intravenous infusion
- 3.5-point NIHSS improvement at 90 days in human trials (CARS, 2015)
- Only peptide with Phase III human trial data
- P21
- CREB signaling, mitochondrial protection, neurogenesis
- 72 hours–6 months (subacute phase)
- 58% reduction in neuronal apoptosis, 35% motor recovery improvement in rodents
- Best evidence for subacute repair window
- MK-677
- IGF-1 elevation, neurogenesis, myelination support
- Subacute to chronic phase
- Oral
- 29% cognitive recovery improvement in aged rodents (2022)
- Indirect support via growth factor modulation
- Thymalin
- Immune modulation, inflammation suppression
- Acute to subacute phase
- Intramuscular
- 38% CRP reduction, improved Barthel Index scores (2020, n=64)
- Targets systemic inflammation post-stroke